Action of Varespladib (LY-315920), a phospholipase A2 inhibitor, on the enzymatic, coagulant and haemorrhagic activities of Lachesis muta rhombeata (South-American Bushmaster) venom

Full metadata record
DC FieldValueLanguage
dc.contributorLab. Herpetologiapt_BR
dc.contributor.authorGutierres, Pamella G.pt_BR
dc.contributor.authorPereira, Diego R.pt_BR
dc.contributor.authorVieira, Nataly L.pt_BR
dc.contributor.authorMorais-Zani, Karen dept_BR
dc.date.accessioned2022-02-04T11:46:07Z-
dc.date.available2022-02-04T11:46:07Z-
dc.date.issued2022pt_BR
dc.identifier.citationGutierres PG., Pereira DR., Vieira NL., Arantes LF., Silva Jr NJ., Torres-Bonilla KA., et al. Action of Varespladib (LY-315920), a phospholipase A2 inhibitor, on the enzymatic, coagulant and haemorrhagic activities of Lachesis muta rhombeata (South-American Bushmaster) venom. Front. Pharmacol. 2022 Jan;12:812295. doi:10.3389/fphar.2021.812295.pt_BR
dc.identifier.urihttps://repositorio.butantan.gov.br/handle/butantan/4137-
dc.description.abstractVarespladib (VPL) was primarily developed to treat inflammatory disturbances associated with high levels of serum phospholipase A2 (PLA2). VPL has also demonstrated to be a potential antivenom support agent to prevent PLA2-dependent effects produced by snake venoms. In this study, we examined the action of VPL on the coagulant, haemorrhagic and enzymatic activities of Lachesis muta rhombeata (South-American bushmaster) venom. Conventional colorimetric enzymatic assays were performed for PLA2, caseinolytic and esterasic activities; in vitro coagulant activities for prothrombin time (PT) and activated partial thromboplastin time (aPTT) were performed in rat citrated plasma through a quick timer coagulometer, whereas the dimensions of haemorrhagic haloes obtained after i.d. injections of venom in Wistar rats were determined using ImageJ software. Venom (1 mg/ml) exhibited accentuated enzymatic activities for proteases and PLA2 in vitro, with VPL abolishing the PLA2 activity from 0.01 mM; VPL did not affect caseinolytic and esterasic activities at any tested concentrations (0.001–1 mM). In rat citrated plasma in vitro, VPL (1 mM) alone efficiently prevented the venom (1 mg/ml)-induced procoagulant disorder associated to extrinsic (PT) pathway, whereas its association with a commercial antivenom successfully prevented changes in both intrinsic (aPTT) and extrinsic (PT) pathways; commercial antivenom by itself failed to avoid the procoagulant disorders by this venom. Venom (0.5 mg/kg)-induced hemorrhagic activity was slightly reduced by VPL (1 mM) alone or combined with antivenom (antivenom:venom ratio 1:3 ‘v/w’) in rats, with antivenom alone producing no protective action on this parameter. In conclusion, VPL does not inhibit other major enzymatic groups of L. m. rhombeata venom, with its high PLA2 antagonize activity efficaciously preventing the venom-induced coagulation disturbances.pt_BR
dc.description.sponsorship(FAPESP) Fundação de Amparo à Pesquisa do Estado de São Paulopt_BR
dc.description.sponsorship(CNPq) Conselho Nacional de Desenvolvimento Científico e Tecnológicopt_BR
dc.format.extent812295pt_BR
dc.language.isoEnglishpt_BR
dc.relation.ispartofFrontiers in Pharmacologypt_BR
dc.rightsOpen accesspt_BR
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/pt_BR
dc.titleAction of Varespladib (LY-315920), a phospholipase A2 inhibitor, on the enzymatic, coagulant and haemorrhagic activities of Lachesis muta rhombeata (South-American Bushmaster) venompt_BR
dc.typeArticlept_BR
dc.rights.licenseCC BYpt_BR
dc.identifier.doi10.3389/fphar.2021.812295pt_BR
dc.contributor.external(UNOESTE) Universidade do Oeste Paulistapt_BR
dc.contributor.external(UFRPE) Universidade Federal Rural de Pernambucopt_BR
dc.contributor.external(PUC-GO) Pontifícia Universidade Católica de Goiáspt_BR
dc.contributor.external(UNICAMP) Universidade Estadual de Campinaspt_BR
dc.contributor.externalUniversity of Strathclydept_BR
dc.identifier.citationvolume12pt_BR
dc.subject.keywordViperidae snakept_BR
dc.subject.keywordphospholipase A2 (PLA2)pt_BR
dc.subject.keywordcoagulating activitypt_BR
dc.subject.keywordhaemorrhagept_BR
dc.subject.keywordvarespladibpt_BR
dc.subject.keywordantivenompt_BR
dc.subject.keywordneutralizationpt_BR
dc.relation.ispartofabbreviatedFront Pharmacolpt_BR
dc.identifier.citationabntv. 12, 812295, jan. 2022pt_BR
dc.identifier.citationvancouver2022 Jan;12:812295pt_BR
dc.contributor.butantanMorais-Zani, Karen de|:Pesquisador|:Lab. Herpetologiapt_BR
dc.sponsorship.butantan(FAPESP) Fundação de Amparo à Pesquisa do Estado de São Paulo¦¦2020/11268-8pt_BR
dc.sponsorship.butantanFundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP)¦¦2021/14375-2pt_BR
dc.sponsorship.butantanFundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP)¦¦2020/04287-6pt_BR
dc.sponsorship.butantan(CNPq) Conselho Nacional de Desenvolvimento Científico e Tecnológico¦¦309320/2016-0pt_BR
dc.sponsorship.butantan(CNPq) Conselho Nacional de Desenvolvimento Científico e Tecnológico¦¦310547/2014-8pt_BR
dc.identifier.bvsccBR78.1pt_BR
dc.identifier.bvsdbIBProdpt_BR
dc.description.dbindexedYespt_BR
item.fulltextCom Texto completo-
item.openairetypeArticle-
item.languageiso639-1English-
item.grantfulltextopen-
crisitem.author.dept#PLACEHOLDER_PARENT_METADATA_VALUE#-
crisitem.author.dept#PLACEHOLDER_PARENT_METADATA_VALUE#-
crisitem.author.dept#PLACEHOLDER_PARENT_METADATA_VALUE#-
crisitem.author.dept#PLACEHOLDER_PARENT_METADATA_VALUE#-
crisitem.author.orcid#PLACEHOLDER_PARENT_METADATA_VALUE#-
crisitem.author.orcid#PLACEHOLDER_PARENT_METADATA_VALUE#-
crisitem.author.orcid#PLACEHOLDER_PARENT_METADATA_VALUE#-
crisitem.author.orcid0000-0001-9900-8384-
crisitem.author.parentorg#PLACEHOLDER_PARENT_METADATA_VALUE#-
crisitem.author.parentorg#PLACEHOLDER_PARENT_METADATA_VALUE#-
crisitem.author.parentorg#PLACEHOLDER_PARENT_METADATA_VALUE#-
crisitem.journal.journalissn#PLACEHOLDER_PARENT_METADATA_VALUE#-
crisitem.journal.journaleissn#PLACEHOLDER_PARENT_METADATA_VALUE#-
Appears in Collections:Artigos


Files in This Item:

fphar-12-812295.pdf
Description:
Size: 1.07 MB
Format: Adobe PDF
View/Open
Show simple item record

This item is licensed under a Creative Commons License Creative Commons